1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. INCYTE CORP.
Incyte Corp.
XNAS: INCY

Incyte Live Stock Price Today, Share Analysis and Chart

Turnaround Potential
about

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheuma...

Read More
98.56 0.79 (0.81%)
66.63% Gain from 52W Low
877.8K
XNAS Volume

XNAS 08 May, 2026 5:30 PM (EDT)

Watchlist

Portfolio

Alert
Board Meeting
The next board meeting for Incyte is on 19 May 2026 for the purpose of RBC 2026 Global Healthcare Conference See details
Durability score
Medium Financial Strength
44.4 / 100
Valuation Score
Affordable Valuation
62.0 / 100
Momentum Score
Technically Moderately Bullish
61.0 / 100
Turnaround Potential These stocks have average financials with good valuations and momentum, indicating turnaround potential View Similar Embed DVM
Analyst Price Target
109
1Yr Price target upside is 10%
22 analysts

18

S

3

W

3

O

2

T

SWOT Analysis

Incyte Live Price Chart

Switch to TradingView


Loading Fundamental data..


Loading data..